Compare AJANTA PHARMA with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ALEMBIC PHARMA AJANTA PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 24.3 17.1 142.6% View Chart
P/BV x 6.8 6.8 99.7% View Chart
Dividend Yield % 0.5 0.6 92.7%  

Financials

 AJANTA PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ALEMBIC PHARMA
Mar-19
AJANTA PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422664 214.1%   
Low Rs898412 217.7%   
Sales per share (Unadj.) Rs233.5208.7 111.9%  
Earnings per share (Unadj.) Rs44.031.0 141.8%  
Cash flow per share (Unadj.) Rs52.237.1 140.5%  
Dividends per share (Unadj.) Rs9.005.50 163.6%  
Dividend yield (eoy) %0.81.0 75.9%  
Book value per share (Unadj.) Rs255.1144.2 176.9%  
Shares outstanding (eoy) m88.02188.52 46.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.6 192.6%   
Avg P/E ratio x26.417.4 151.9%  
P/CF ratio (eoy) x22.214.5 153.3%  
Price / Book Value ratio x4.53.7 121.8%  
Dividend payout %20.517.7 115.4%   
Avg Mkt Cap Rs m102,081101,461 100.6%   
No. of employees `0006.8NA-   
Total wages/salary Rs m4,3077,467 57.7%   
Avg. sales/employee Rs Th3,022.6NM-  
Avg. wages/employee Rs Th633.4NM-  
Avg. net profit/employee Rs Th569.1NM-  
INCOME DATA
Net Sales Rs m20,55439,347 52.2%  
Other income Rs m21194 224.7%   
Total revenues Rs m20,76539,441 52.6%   
Gross profit Rs m5,6648,736 64.8%  
Depreciation Rs m7211,152 62.6%   
Interest Rs m12184 6.3%   
Profit before tax Rs m5,1437,493 68.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2731,568 81.2%   
Profit after tax Rs m3,8705,844 66.2%  
Gross profit margin %27.622.2 124.1%  
Effective tax rate %24.820.9 118.3%   
Net profit margin %18.814.9 126.8%  
BALANCE SHEET DATA
Current assets Rs m11,81219,577 60.3%   
Current liabilities Rs m3,77614,896 25.4%   
Net working cap to sales %39.111.9 328.6%  
Current ratio x3.11.3 238.0%  
Inventory Days Days7790 86.2%  
Debtors Days Days8245 179.9%  
Net fixed assets Rs m14,39827,097 53.1%   
Share capital Rs m175377 46.5%   
"Free" reserves Rs m22,27726,811 83.1%   
Net worth Rs m22,45227,188 82.6%   
Long term debt Rs m74,993 0.1%   
Total assets Rs m26,96247,778 56.4%  
Interest coverage x444.341.7 1,065.5%   
Debt to equity ratio x00.2 0.2%  
Sales to assets ratio x0.80.8 92.6%   
Return on assets %14.412.6 114.1%  
Return on equity %17.221.5 80.2%  
Return on capital %23.023.6 97.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68219,453 54.9%   
Fx outflow Rs m2,1026,065 34.7%   
Net fx Rs m8,58013,388 64.1%   
CASH FLOW
From Operations Rs m3,7488,120 46.2%  
From Investments Rs m-2,228-7,556 29.5%  
From Financial Activity Rs m-1,475590 -249.8%  
Net Cashflow Rs m451,153 3.9%  

Share Holding

Indian Promoters % 73.8 74.1 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.9 53.4%  
FIIs % 7.6 9.1 83.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 13.9 122.3%  
Shareholders   20,968 49,328 42.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ABBOTT INDIA  NATCO PHARMA  ELDER PHARMA  PFIZER  ALKEM LABORATORIES  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS